Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease

Amy E. Lovett-Racke, Rehana Z. Hussain, Sara Northrop, Judy Choy, Anne Rocchini, Lela Matthes, Janet A. Chavis, Asim Diab, Paul D. Drew, Michael K. Racke

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily. PPARγ ligands, which include the naturally occurring PG metabolite 15-deoxy-Δ12,14-PGJ 2 (15d-PGJ2), as well as thiazolidinediones, have been shown to have anti-inflammatory activity. The PPARα agonists, gemfibrozil, ciprofibrate, and fenofibrate, have an excellent track history as oral agents used to treat hypertriglyceridemia. In the present study, we demonstrate that these PPARα agonists can increase the production of the Th2 cytokine, IL-4, and suppress proliferation by TCR transgenic T cells specific for the myelin basic protein Ac1-11, as well as reduce NO production by microglia. Oral administration of gemfibrozil and fenofibrate inhibited clinical signs of experimental autoimmune encephalomyelitis. More importantly, gemfibrozil was shown to shift the cytokine secretion of human T cell lines by inhibiting IFN-γ and promoting IL-4 secretion. These results suggest that PPARα agonists such as gemfibrozil and fenofibrate, may be attractive candidates for use in human inflammatory conditions such as multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)5790-5798
Number of pages9
JournalJournal of Immunology
Volume172
Issue number9
StatePublished - May 1 2004

Fingerprint

Peroxisome Proliferator-Activated Receptors
Gemfibrozil
Autoimmune Diseases
Fenofibrate
Interleukin-4
Cytokines
T-Lymphocytes
Therapeutics
Thiazolidinediones
Autoimmune Experimental Encephalomyelitis
Hypertriglyceridemia
Microglia
Cytoplasmic and Nuclear Receptors
Multiple Sclerosis
Oral Administration
Anti-Inflammatory Agents
Interviews
Ligands
Cell Line

ASJC Scopus subject areas

  • Immunology

Cite this

Lovett-Racke, A. E., Hussain, R. Z., Northrop, S., Choy, J., Rocchini, A., Matthes, L., ... Racke, M. K. (2004). Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease. Journal of Immunology, 172(9), 5790-5798.

Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease. / Lovett-Racke, Amy E.; Hussain, Rehana Z.; Northrop, Sara; Choy, Judy; Rocchini, Anne; Matthes, Lela; Chavis, Janet A.; Diab, Asim; Drew, Paul D.; Racke, Michael K.

In: Journal of Immunology, Vol. 172, No. 9, 01.05.2004, p. 5790-5798.

Research output: Contribution to journalArticle

Lovett-Racke, AE, Hussain, RZ, Northrop, S, Choy, J, Rocchini, A, Matthes, L, Chavis, JA, Diab, A, Drew, PD & Racke, MK 2004, 'Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease', Journal of Immunology, vol. 172, no. 9, pp. 5790-5798.
Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L et al. Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease. Journal of Immunology. 2004 May 1;172(9):5790-5798.
Lovett-Racke, Amy E. ; Hussain, Rehana Z. ; Northrop, Sara ; Choy, Judy ; Rocchini, Anne ; Matthes, Lela ; Chavis, Janet A. ; Diab, Asim ; Drew, Paul D. ; Racke, Michael K. / Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease. In: Journal of Immunology. 2004 ; Vol. 172, No. 9. pp. 5790-5798.
@article{ac192c7494374d0fa14223b114b8924d,
title = "Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease",
abstract = "Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily. PPARγ ligands, which include the naturally occurring PG metabolite 15-deoxy-Δ12,14-PGJ 2 (15d-PGJ2), as well as thiazolidinediones, have been shown to have anti-inflammatory activity. The PPARα agonists, gemfibrozil, ciprofibrate, and fenofibrate, have an excellent track history as oral agents used to treat hypertriglyceridemia. In the present study, we demonstrate that these PPARα agonists can increase the production of the Th2 cytokine, IL-4, and suppress proliferation by TCR transgenic T cells specific for the myelin basic protein Ac1-11, as well as reduce NO production by microglia. Oral administration of gemfibrozil and fenofibrate inhibited clinical signs of experimental autoimmune encephalomyelitis. More importantly, gemfibrozil was shown to shift the cytokine secretion of human T cell lines by inhibiting IFN-γ and promoting IL-4 secretion. These results suggest that PPARα agonists such as gemfibrozil and fenofibrate, may be attractive candidates for use in human inflammatory conditions such as multiple sclerosis.",
author = "Lovett-Racke, {Amy E.} and Hussain, {Rehana Z.} and Sara Northrop and Judy Choy and Anne Rocchini and Lela Matthes and Chavis, {Janet A.} and Asim Diab and Drew, {Paul D.} and Racke, {Michael K.}",
year = "2004",
month = "5",
day = "1",
language = "English (US)",
volume = "172",
pages = "5790--5798",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "9",

}

TY - JOUR

T1 - Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease

AU - Lovett-Racke, Amy E.

AU - Hussain, Rehana Z.

AU - Northrop, Sara

AU - Choy, Judy

AU - Rocchini, Anne

AU - Matthes, Lela

AU - Chavis, Janet A.

AU - Diab, Asim

AU - Drew, Paul D.

AU - Racke, Michael K.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily. PPARγ ligands, which include the naturally occurring PG metabolite 15-deoxy-Δ12,14-PGJ 2 (15d-PGJ2), as well as thiazolidinediones, have been shown to have anti-inflammatory activity. The PPARα agonists, gemfibrozil, ciprofibrate, and fenofibrate, have an excellent track history as oral agents used to treat hypertriglyceridemia. In the present study, we demonstrate that these PPARα agonists can increase the production of the Th2 cytokine, IL-4, and suppress proliferation by TCR transgenic T cells specific for the myelin basic protein Ac1-11, as well as reduce NO production by microglia. Oral administration of gemfibrozil and fenofibrate inhibited clinical signs of experimental autoimmune encephalomyelitis. More importantly, gemfibrozil was shown to shift the cytokine secretion of human T cell lines by inhibiting IFN-γ and promoting IL-4 secretion. These results suggest that PPARα agonists such as gemfibrozil and fenofibrate, may be attractive candidates for use in human inflammatory conditions such as multiple sclerosis.

AB - Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily. PPARγ ligands, which include the naturally occurring PG metabolite 15-deoxy-Δ12,14-PGJ 2 (15d-PGJ2), as well as thiazolidinediones, have been shown to have anti-inflammatory activity. The PPARα agonists, gemfibrozil, ciprofibrate, and fenofibrate, have an excellent track history as oral agents used to treat hypertriglyceridemia. In the present study, we demonstrate that these PPARα agonists can increase the production of the Th2 cytokine, IL-4, and suppress proliferation by TCR transgenic T cells specific for the myelin basic protein Ac1-11, as well as reduce NO production by microglia. Oral administration of gemfibrozil and fenofibrate inhibited clinical signs of experimental autoimmune encephalomyelitis. More importantly, gemfibrozil was shown to shift the cytokine secretion of human T cell lines by inhibiting IFN-γ and promoting IL-4 secretion. These results suggest that PPARα agonists such as gemfibrozil and fenofibrate, may be attractive candidates for use in human inflammatory conditions such as multiple sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=11144357288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144357288&partnerID=8YFLogxK

M3 - Article

VL - 172

SP - 5790

EP - 5798

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 9

ER -